Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06016192
Other study ID # PCS_Training_01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2021
Est. completion date May 31, 2023

Study information

Verified date August 2023
Source University of Witten/Herdecke
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Post-COVID-19 syndrome (PCS) occurs as a sequelae after acute infection with the SARS-CoV-2 virus (COVID-19 infection). PCS is defined as symptom persistence over a period of 12 weeks from infection and/or the appearance of new symptoms in this period. While the majority of affected patients experience a gradual healing process without targeted treatment, the need for effective medical rehabilitation is high at least for patients with persistent PCS. Given that physical exercise has been shown to be beneficial in multiple pathologies such as cardiovascular diseases, neuropathic disorders, and pulmonary diseases it has been suggested that physical exercise including aerobic training could exert beneficial effects also in PCS. This study aims to analyse the use of moderate-intensity aerobic exercise training for medical rehabilitation of PCS patients.


Description:

Post-COVID-19 syndrome (PCS) is a condition that occurs following an acute infection with the SARS-CoV-2 virus (COVID-19). PCS is characterized by symptom persistence for at least 12 weeks after the infection or the emergence of new symptoms during this period. Current guidelines propose several criteria for diagnosing PCS, including persistent symptoms from the acute COVID-19 phase, new symptoms leading to health limitations, symptoms assumed to be related to COVID-19 after the acute phase, and worsening of pre-existing underlying conditions. PCS is a complex and multisystemic disorder, with symptoms ranging from chronic fatigue, decreased physical performance, muscular weakness, and pain to cognitive impairment (often referred to as brain fog) and mental and psychological distress resembling a post-traumatic stress reaction. The exact causes of PCS are not fully understood but may involve processes such as endothelial dysfunction, cytokine storm, and increased oxidative stress affecting various organs and structures in the body. The incidence of PCS varies depending on the population studied and the severity of symptoms considered, with estimates ranging from 7.5% to 41% among non-hospitalized patients with acute infection. Medical rehabilitation is essential for patients with persistent PCS, but there are limited studies on its efficacy, especially in the context of aerobic endurance training. Physical exercise, including aerobic training, has shown positive effects in various diseases, and it is suggested that it may be beneficial for PCS as well. However, there is limited evidence regarding the effectiveness of aerobic endurance training in reducing the burden of decreased physical performance in PCS. Moreover, there is a lack of guidelines for PCS patients related to exercise-based rehabilitation. Aerobic endurance training has been proven to have positive effects on multiple physiological functions and is recommended for chronic heart and pulmonary diseases. Studies have also suggested that aerobic interval training may be advantageous for PCS patients, as it reduces ventilatory demand and may alleviate dyspnea and breathing effort. This study aims to investigate the efficacy of moderate-intensity aerobic endurance training performed as either continuous training and interval training for the medical rehabilitation of PCS patients. The study will include PCS patients referred for inpatient medical rehabilitation in Germany with a history of (at least one) Covid-19 infection and ongoing or newly expressed performance deficits lasting for at least 3 months prior to recruitment. Performance deficits will be documented according to the recent consensus statement, with the cluster of lead symptoms including fatigue/exercise intolerance, shortness of breath, and cognitive dysfunction impairing activity of daily living and everyday functioning. A detailed clinical workup will be performed, and the history of comorbidities and current medication will be documented. After admission, patients will be randomized to a continuous training (CT) or interval training (IT) group. Patients will receive individual medical rehabilitation including a combination of strength, respiratory and cognitive training, as well as physio-, psycho- and nutrition therapy, unaltered for both groups. Data on medical rehabilitation including prescriptions of therapeutic actions and participation will be recorded for all patients. Symptom-limited spiroergometry at admission and after 4-6 weeks of inpatient rehabilitation (before discharge) will be performed to analyze improvements in exercise capacity. Validated questionnaires will be used to document patients' disease perception.


Recruitment information / eligibility

Status Completed
Enrollment 139
Est. completion date May 31, 2023
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - a history of (at least one) Covid-19 infection - ongoing or newly expressed performance deficits lasting for at least 3 months prior to recruitment - referral to inpatient rehabilitation - signed informed consent Exclusion Criteria: - unstable condition - incapable of understanding study information

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Aerobic Exercise Training
Physical activity performed as controlled aerobic exercise training on ergometer

Locations

Country Name City State
Germany Clinic Königsfeld Ennepetal NRW

Sponsors (2)

Lead Sponsor Collaborator
University of Witten/Herdecke Institut für Rehabilitationsforschung Norderney

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in training load Training load will be assessed by analysis of documented ergometer settings (mean Watts) Daily, from baseline to week 4 (i. e. before discharge)
Other Training participation Training participation will be assessed by number of performed ergometer training sessions Daily, from baseline to week 4 (i. e. before discharge)
Other Change in minute ventilation (VE) Minute ventilation will be determined by spiroergometry measuring breath-by-breath volumes (ml) Baseline and week 4 (i. e. before discharge)
Other Change in carbon dioxide production (VCO2) Carbon dioxide production (VCO2) will be determined by spiroergometry measuring breath-by-breath volumes of exhaled carbon dioxide (ml) Baseline and week 4 (i. e. before discharge)
Other Change in submaximal and maximal workload (Watt) Submaxmal and maximal workload (Watt) will be determined by spiroergometry Baseline and week 4 (i. e. before discharge)
Primary Change in Cardiorespiratory Fitness (CRF) CRF will be measured as peak oxygen uptake (VO2peak) determined by spiroergometry Baseline and week 4 (i. e. before discharge)
Secondary Change in Submaximal Cardiorespiratory Fitness (CRF) Submaximal CRF will be measured as submaximal oxygen uptake (VO2 at ventilatory threshold 1 [VT1]) determined by spiroergometry Baseline and week 4 (i. e. before discharge)
Secondary Change in Fatigue Fatigue will be assessed using the "The Multidimensional Fatigue Inventory (MFI20)". Baseline and week 4 (i. e. before discharge)
Secondary Work requirements and workload Work requirements and workload will be assessed using the "Workability Index (WAI)". Baseline
Secondary Change Health-related quality of life Health-related quality of life will be assessed using the "RAND 36-Item Health Survey (SF-36)". Baseline and week 4 (i. e. before discharge)
Secondary Wellbeing Wellbeing will be assessed using the "WHO-5 Well-Being Index". Baseline and week 4 (i. e. before discharge)
Secondary Change in Depression and Anxiety Depression and Anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS) Baseline and week 4 (i. e. before discharge)
See also
  Status Clinical Trial Phase
Recruiting NCT06073002 - Effects of a Home-Based Exercise Intervention in Subjects With Long COVID N/A
Completed NCT05047952 - Vortioxetine for Post-COVID-19 Condition Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Not yet recruiting NCT06267300 - Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial Phase 3
Recruiting NCT05986422 - Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Phase 2
Not yet recruiting NCT05534997 - Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome N/A
Recruiting NCT05638633 - Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome Phase 3
Active, not recruiting NCT05630040 - VNS for Long-COVID-19 N/A
Recruiting NCT05841498 - Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome N/A
Enrolling by invitation NCT05981872 - EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19 N/A
Active, not recruiting NCT05543408 - Long COVID-19 Syndrome in Primary Care: A Novel Protocol of Exercise Intervention "CON-VIDA Clinical Trial" N/A
Recruiting NCT05817032 - Effect of Telerehabilitation Practice in Long COVID-19 Patients N/A
Recruiting NCT05823896 - imPROving Quality of LIFe In the Long COVID Patient Phase 2
Completed NCT05764070 - Impact of Vagus Nerve Stimulation on Post-Aerobic Activity Recovery in Post SARS-CoV-2 Patients N/A
Completed NCT05765591 - Balneotherapy for Patients With Post-acute Coronavirus Disease (COVID) Syndrome N/A
Recruiting NCT05918965 - Vagus Stimulation in Female Long COVID Patients. N/A
Not yet recruiting NCT06231238 - Balance Acceptance and Commitment Therapy for Long COVID Phase 2
Completed NCT06282627 - The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
Completed NCT05648734 - Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis